In the latest trading session, 0.63 million ATAI Life Sciences N.V (NASDAQ:ATAI) shares changed hands as the company’s beta touched 1.13. With the company’s most recent per share price at $1.21 changed hands at -$0.1 or -7.76% at last look, the market valuation stands at $239.61M. ATAI’s current price is a discount, trading about -118.18% off its 52-week high of $2.64. The share price had its 52-week low at $1.03, which suggests the last value was 14.88% up since then. When we look at ATAI Life Sciences N.V’s average trading volume, we note the 10-day average is 1.95 million shares, with the 3-month average coming to 2.81 million.
Analysts gave the ATAI Life Sciences N.V (ATAI) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended ATAI as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. ATAI Life Sciences N.V’s EPS for the current quarter is expected to be -0.18.
ATAI Life Sciences N.V (NASDAQ:ATAI) trade information
Instantly ATAI was in red as seen in intraday trades today. With action -11.15%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -9.15%, with the 5-day performance at -11.15% in the red. However, in the 30-day time frame, ATAI Life Sciences N.V (NASDAQ:ATAI) is -19.98% down. Looking at the short shares, we see there were 10.4 million shares sold at short interest cover period of 3.61 days.
The consensus price target for the stock as assigned by Wall Street analysts is 6, meaning bulls need an upside of 79.83% from its recent market value. According to analyst projections, ATAI’s forecast low is 6 with 6 as the target high. To hit the forecast high, the stock’s price needs a -395.87% plunge from its current level, while the stock would need to soar -395.87% for it to hit the projected low.
ATAI Life Sciences N.V (ATAI) estimates and forecasts
Year-over-year growth is forecast to reach -18.83% down from the last financial year.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at -100.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 18.62%. The 2025 estimates are for ATAI Life Sciences N.V earnings to increase by 24.17%, but the outlook for the next 5-year period is at 17.72% per year.
ATAI Life Sciences N.V (NASDAQ:ATAI)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 8.58% of ATAI Life Sciences N.V shares while 29.18% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 31.92%. There are 29.18% institutions holding the ATAI Life Sciences N.V stock share, with WALLEYE CAPITAL LLC the top institutional holder. As of 2024-06-30, the company held 1.7226% of the shares, roughly 2.76 million ATAI shares worth $3.67 million.
MORGAN STANLEY holds the second largest percentage of outstanding shares, with 1.6952% or 2.72 million shares worth $3.62 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were MORGAN STANLEY INSTITUTIONAL FUND INC-Inception Portfolio and AdvisorShares Trust-AdvisorShares Psychedelics ETF. With 511.99 shares estimated at $0.65 million under it, the former controlled 0.26% of total outstanding shares. On the other hand, AdvisorShares Trust-AdvisorShares Psychedelics ETF held about 0.21% of the shares, roughly 408.76 shares worth around $0.52 million.
